Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

This study is looking at whether dental cleanings can help prevent chronic graft-versus-host disease (GVHD) in people who have had a stem cell transplant (HCT). HCT is a treatment for some blood cancers, but it can sometimes lead to GVHD, where the new cells attack your body. Some research suggests that bacteria in your mouth might play a role in developing chronic GVHD. This trial will provide a dental cleaning around 28 days after your transplant. Researchers will then see if this helps reduce the chance of developing moderate-to-severe chronic GVHD one year after your transplant. You might be able to join if you are 18 or older, have had a specific type of HCT, and are willing to have a follow-up visit one year later. The current status of this study is unclear, and it plans to enroll 45 participants.

Study design
This is an interventional study planning to enroll 45 participants. It involves a dental cleaning procedure after a stem cell transplant.
What's involved
You would receive a simplified dental cleaning around 28 days after your transplant. You will then have follow-up visits on days +84, +180, and at 1 year.
Compensation
Not stated in the trial record.
Follow-up
Participants are followed up on days +84 and +180, and at 1 year after the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07535008

Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

Recruiting
NAAges 18+InterventionalPrevention
Fred Hutchinson Cancer Center
~45 participants
Updated 2026-08-12 on ClinicalTrials.gov
What's tested:Dental CleaningDental Plaque sampling

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Probability of moderate-to-severe chronic graft versus host disease
Measured over At 1-year post-transplant
Chronic Graft Versus Host Disease
Acute Graft Versus Host Disease
Hematopoietic and Lymphatic System Neoplasm

NCT07535008

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washingtonstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Armin Rashidi, MD, PhD · PRINCIPAL_INVESTIGATOR · Fred Hutch/University of Washington Cancer Consortium

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years old
T-replete allogeneic hematopoietic cell transplantation for any indication. History of prior transplantation is allowed. Any conditioning regimen is allowed
One of the following HCT donor types:
9/10 or 10/10 human leukocyte antigen (HLA)-matched unrelated donor
Cord blood
Willing to have an in-person 1-year long-term follow-up (LTFU) visit including an oral medicine at Fred Hutch (FH)
Ability to understand and sign a written informed consent document (or legal representative)

Exclusion

Edentulous state
Bone marrow as graft source
Use of post-transplantation cyclophosphamide (PTCy) or ruxolitinib as GVHD prophylaxis
Use of anti-thymocyte globulin (ATG) in conditioning
  • Probability of moderate-to-severe chronic graft versus host diseaseAt 1-year post-transplant